Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 7;22(24):6204–6216. doi: 10.1158/1078-0432.CCR-15-3059

Figure 4. Fulvestrant reverts immune resistance of chemo-resistant lung cancer cells.

Figure 4

(A) Fold change in expression levels of indicated mRNA in chemo-resistant vs. control H1703 cells. (B) Immunofluorescent analysis of ESR1 (pink signal) in control and cisplatin/vinorelbine-resistant (Cis/Vin) H1703 cells. Blue signal corresponds to DAPI staining. (C) Susceptibility of control H1703 vs. Cis/Vin-resistant H1703 cells to lysis by either TRAIL (left panel) or NK cells (right panel). Chemo-resistant cells were treated with DMSO or fulvestrant for 72 hours prior to the cytotoxic assay. (D) Sensitivity of control vs. Cis/Vin-resistant H1703 cells to a combination of indicated concentrations of vinorelbine and cisplatin; tumor cells were treated with DMSO (left panel) or fulvestrant (right panel) for 72 hours prior to exposure to chemotherapy. (E) Immunohistochemical analysis of ESR1 expression in H460 xenografts from mice treated with either HBSS or docetaxel (20× magnification). (F) Immunofluorescent analysis of ESR1 expression (pink signal) in control and Cis/Vin-resistant H460 cells (100× magnification). Green and blue correspond to phalloidin and DAPI staining, respectively. (G) Fold-change in expression levels of indicated mRNA in Cis/Vin-resistant vs. control H460 cells (H) Susceptibility of parental vs. chemo-resistant H460 cells to lysis by MUC1-specific CD8+ T cells. Chemo-resistant cells were treated with DMSO or fulvestrant for 72 hours prior to the cytotoxic assay. (I) TRAIL-mediated lysis of parental H460 vs. chemo-resistant H460 cells previously transfected with a control non-targeting Con siRNA vs. a pool of siRNAs targeting either brachyury (T siRNA) or the estrogen receptor 1 (ESR1 siRNA). Error bars indicate the standard error of the mean (SEM) of triplicate measurements. [* p<0.05, ** p<0.01].